Vaccinex Collaborates with Merck in HNSCC Study

, , , , , , , , , ,

Vaccinex Inc. will pair the company’s lead asset pepinemab with Merck & Co.’s vaunted checkpoint inhibitor Keytruda.

Read more
/by